Ser444
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser444  -  SSRP1 (mouse)

Site Information
GYDDyADsDEDQHDA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 449120
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 )
Disease tissue studied:
anthrax infection ( 20 ) , leukemia ( 13 , 41 ) , acute myelogenous leukemia ( 13 ) , lung cancer ( 45 , 46 , 47 , 48 ) , non-small cell lung cancer ( 45 , 46 , 47 , 48 ) , melanoma skin cancer ( 43 ) , testicular cancer ( 25 )
Relevant cell line - cell type - tissue:
'3T3-L1, differentiated' (adipocyte) ( 2 , 8 ) , 'brain, cerebral cortex' ( 33 ) , 'brain, embryonic' ( 39 , 40 ) , 'fat, brown' ( 21 ) , 'stem, embryonic' ( 27 , 28 , 29 , 30 , 31 , 32 , 37 ) , 32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ( 34 ) , 32Dcl3 (myeloid) ( 34 ) , 3T3 (fibroblast) [KRas (human), transfection] ( 6 ) , 3T3 (fibroblast) ( 6 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , blood ( 13 ) , brain ( 14 , 15 , 21 , 23 ) , C2C12 (myoblast) ( 16 , 35 ) , F9 (testicular) ( 25 ) , heart ( 9 , 21 , 38 , 50 ) , Hepa 1-6 (epithelial) ( 44 ) , kidney ( 21 ) , liver ( 7 , 12 , 21 , 36 , 49 , 51 , 52 ) , liver [leptin (mouse), homozygous knockout] ( 12 ) , lung ( 21 ) , macrophage-bone marrow ( 22 ) , macrophage-bone marrow [DUSP1 (mouse), homozygous knockout] ( 22 ) , macrophage-peritoneum ( 11 ) , MC3T3-E1 (preosteoblast) ( 3 ) , MEF (fibroblast) ( 10 , 18 ) , MEF (fibroblast) [p53 (mouse), homozygous knockout] ( 17 ) , MEF (fibroblast) [Raptor (mouse), knockdown] ( 10 ) , MEF (fibroblast) [RICTOR (mouse), knockdown] ( 10 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 18 ) , mpkCCD (renal) ( 24 ) , pancreas ( 21 ) , RAW 264.7 (macrophage) ( 4 , 41 ) , RAW 267.4 (macrophage) ( 42 ) , skin [mGluR1 (mouse), transgenic, TG mutant mice] ( 43 ) , spleen ( 20 , 21 ) , stromal ( 5 ) , T lymphocyte-spleen ( 19 ) , testis ( 21 )

Upstream Regulation
Treatments:
BMP2 ( 35 ) , IFN-gamma ( 42 )

References 

1

Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia
28852199   Curated Info

2

Minard AY, et al. (2016) mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes. Cell Rep 17, 29-36
27681418   Curated Info

3

Williams GR, et al. (2016) Exploring G protein-coupled receptor signaling networks using SILAC-based phosphoproteomics. Methods 92, 36-50
26160508   Curated Info

4

Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44
25367039   Curated Info

5

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

6

Gnad F, et al. (2013) Systems-wide Analysis of K-Ras, Cdc42, and PAK4 Signaling by Quantitative Phosphoproteomics. Mol Cell Proteomics 12, 2070-80
23608596   Curated Info

7

Wilson-Grady JT, Haas W, Gygi SP (2013) Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61, 277-86
23567750   Curated Info

8

Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622   Curated Info

9

Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11
23737553   Curated Info

10

Robitaille AM, et al. (2013) Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320-3
23429704   Curated Info

11

Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51
22942356   Curated Info

12

Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83
23140645   Curated Info

13

Trost M, et al. (2012) Posttranslational regulation of self-renewal capacity: insights from proteome and phosphoproteome analyses of stem cell leukemia. Blood 120, e17-27
22802335   Curated Info

14

Trinidad JC, et al. (2012) Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol Cell Proteomics 11, 215-29
22645316   Curated Info

15

Goswami T, et al. (2012) Comparative phosphoproteomic analysis of neonatal and adult murine brain. Proteomics 12, 2185-9
22807455   Curated Info

16

Knight JD, et al. (2012) A novel whole-cell lysate kinase assay identifies substrates of the p38 MAPK in differentiating myoblasts. Skelet Muscle 2, 5
22394512   Curated Info

17

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

18

Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6
21659605   Curated Info

19

Navarro MN, et al. (2011) Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes. Nat Immunol 12, 352-61
21399638   Curated Info

20

Manes NP, et al. (2011) Discovery of mouse spleen signaling responses to anthrax using label-free quantitative phosphoproteomics via mass spectrometry. Mol Cell Proteomics 10, M110.000927
21189417   Curated Info

21

Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89
21183079   Curated Info

22

Weintz G, et al. (2010) The phosphoproteome of toll-like receptor-activated macrophages. Mol Syst Biol 6, 371
20531401   Curated Info

23

Wiśniewski JR, et al. (2010) Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res 9, 3280-9
20415495   Curated Info

24

Rinschen MM, et al. (2010) Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells. Proc Natl Acad Sci U S A 107, 3882-7
20139300   Curated Info

25

Zhou J (2010) CST Curation Set: 9105; Year: 2010; Biosample/Treatment: cell line, F9/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

26

Zhou J (2010) CST Curation Set: 9104; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

27

Tucker M (2009) CST Curation Set: 8089; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

28

Tucker M (2009) CST Curation Set: 8084; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

29

Tucker M (2009) CST Curation Set: 8088; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

30

Tucker M (2009) CST Curation Set: 8085; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

31

Tucker M (2009) CST Curation Set: 8080; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

32

Tucker M (2009) CST Curation Set: 8072; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

33

Tweedie-Cullen RY, Reck JM, Mansuy IM (2009) Comprehensive mapping of post-translational modifications on synaptic, nuclear, and histone proteins in the adult mouse brain. J Proteome Res 8, 4966-82
19737024   Curated Info

34

Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39
19854140   Curated Info

35

Kim BG, et al. (2009) 'Two-stage double-technique hybrid (TSDTH)' identification strategy for the analysis of BMP2-induced transdifferentiation of premyoblast C2C12 cells to osteoblast. J Proteome Res 8, 4441-54
19655815   Curated Info

36

Guo A (2009) CST Curation Set: 7773; Year: 2009; Biosample/Treatment: tissue, liver(STK11)/Metformin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

37

Li H, et al. (2009) SysPTM: a systematic resource for proteomic research on post-translational modifications. Mol Cell Proteomics 8, 1839-49
19366988   Curated Info

38

Zhou J (2009) CST Curation Set: 7386; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST]
Curated Info

39

Zhou J (2009) CST Curation Set: 7381; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST]
Curated Info

40

Zhou J (2009) CST Curation Set: 7382; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST]
Curated Info

41

Possemato A (2009) CST Curation Set: 7167; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/LPS; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

42

Trost M, et al. (2009) The phagosomal proteome in interferon-gamma-activated macrophages. Immunity 30, 143-54
19144319   Curated Info

43

Zanivan S, et al. (2008) Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res 7, 5314-26
19367708   Curated Info

44

Pan C, Gnad F, Olsen JV, Mann M (2008) Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 8, 4534-46
18846507   Curated Info

45

Rikova K (2008) CST Curation Set: 4249; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

46

Rikova K (2008) CST Curation Set: 4250; Year: 2008; Biosample/Treatment: tissue, lung/Tarceva; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

47

Rikova K (2008) CST Curation Set: 4251; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

48

Rikova K (2008) CST Curation Set: 4252; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

49

Guo A (2007) CST Curation Set: 2921; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S*/T*D/EXD/E) Immunoaffinity Beads Cat#: 1994
Curated Info

50

Guo A (2007) CST Curation Set: 2923; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S*/T*D/EXD/E) Immunoaffinity Beads Cat#: 1994
Curated Info

51

Villén J, Beausoleil SA, Gerber SA, Gygi SP (2007) Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A 104, 1488-93
17242355   Curated Info

52

Dai J, et al. (2007) Protein phosphorylation and expression profiling by Yin-yang multidimensional liquid chromatography (Yin-yang MDLC) mass spectrometry. J Proteome Res 6, 250-62
17203969   Curated Info